Total Brain Limited Overview
For over two decades, Total Brain Limited, previously Brain Resource, sat at the meeting point of academic neuroscience and commercial digital health. It built what it called the world's largest standardized brain database. That database came from the Brain Resource International Database and the landmark iSPOT-Depression and iSPOT-ADHD treatment-prediction studies. Between 2018 and 2022, the company repackaged this scientific asset into "Total Brain". This was a SaaS mental-health monitoring and self-care platform sold to US employers, affinity groups, insurers, clinical providers and government programs, including an IBM-led deployment for the US Department of Veterans Affairs. The science was credible and the partners were blue-chip. Even so, revenue stayed small: roughly A$2.6m in FY2019 and A$8.4m in FY2022, the latter flattered by one-off data licences. Cash burn was persistent, and in August 2022 the board agreed to sell the business to SonderMind for US$10m. Total Brain is best understood today as a completed exit and a case study in sub-scale digital-health commercialization. It is no longer an investable listed entity.
Company's own description (FY2019–FY2022 filings and releases). Total Brain described itself as an applied, integrative neuroscience company. It said it had built a mental health monitoring and support platform powered by the world's largest standardized brain database. The platform was meant to let individuals scientifically measure and optimize their brain capacities while managing the risk of common mental conditions (FY2019 Annual Report; ASX quarterly 4C releases 2019–2021). It claimed to measure 12 brain capacities that define mental health and to screen for the risk of 7 common mental health conditions (company investor update, early 2021, as reported by Stockhead).
Business model. Total Brain operated a business-to-business-to-consumer (B2B2C) SaaS model. Paying customers were organizations, not individuals:
Revenue mix characterization. Revenue was mostly subscription SaaS, with occasional large licensing items. In FY2022 (A$8.42m reported revenue, per MarketScreener aggregation of the FY2022 annual report), a material but not separately verified share came from the one-off Janssen and Alto data licences. That means FY2022 headline revenue overstates the recurring run-rate. ARR, the better recurring measure, was about A$4.0m at December 2020 (+46% YoY) (company update, Jan 2021, reported by Stockhead).
Value chain position. Total Brain was an upstream "measurement and insight" layer. It assessed, screened and tracked brain-health capacities and delivered self-care exercises, but it did not provide therapy or clinical treatment. That gap is exactly why SonderMind acquired it: SonderMind delivers therapy and wanted measurement-based-care tooling upstream and downstream of the therapy session.
End-markets served. Employer mental-health benefits (corporate wellness and EAP adjacency), consumer brain fitness, behavioral-health measurement-based care, veteran and government transition programs, and pharmaceutical precision-psychiatry R&D.
Independent characterization. Total Brain's lasting asset was its scientific data (iSPOT-D, iSPOT-ADHD, the standardized brain database of more than one million users), not its software. Within one year it monetized that data twice through one-off licences (Janssen, Alto). In the same period, the employer SaaS business competed against far better-funded US venture-backed platforms (Lyra, Spring Health, Modern Health, Headspace/Ginger). The business therefore depended on financing: the board repeatedly raised equity (A$10m in FY2018, A$14m in November 2019) and convertible debt (A$1.28m, April 2022) to fund operating outflows of about A$2.9m per quarter by late 2021.
Strategy
Stated strategy themes (FY2019–FY2021 annual reports and quarterlies), paraphrased:
-
Science as the moat. Use the standardized brain database and about two decades of validated neuroscience to separate Total Brain from consumer brain-training and meditation apps.
-
B2B2C distribution. Grow Corporate ARR by penetrating existing channel partners and running account-based marketing aimed at the largest US enterprises. FY2019 produced more than 160 new marketing leads (Kalkine, Sept 2019).
-
Three-channel growth engine: Corporate, Affinity and Clinical, with an ARR pipeline of A$8.9m flagged in January 2021.
-
Government scale via IBM. Use IBM's Mental Fitness 360 to reach populations in transition, starting with US veterans (18m potential population cited).
-
Operating leverage. Hold the cost base roughly flat while growing revenue. Management said in January 2021 that 2020 investments had positioned the company for this.
-
Product extension. Biometrics (HRV wearables), genetics and clinical measurement-based care.
-
Data monetization. Non-exclusive licensing of iSPOT-D and other research data to pharma and precision-psychiatry developers (2021–2022).
Medium-term targets. In CY2019, management set an objective of 100% revenue growth to US$3.2m and 100% growth in user registrations and Brain Profiles (Dec 2018 quarterly). This was not met: FY2020 revenue was about A$3.9m, roughly US$2.6m. There was no guidance after the sale. ESG commitments and cost-program targets were not publicly disclosed.
Product Portfolio
| Product / asset | Description | Key capabilities | Target customer | Launch / latest | Pricing model |
|---|---|---|---|---|---|
Total Brain platform (core) | Neuroscience-based mental health and brain-performance monitoring and self-care SaaS app (web, iOS, Android) | Assesses 12 brain capacities across core domains (emotion, feeling, cognition, self-control); screens risk for 7 common conditions; personalized brain and mind/body training; longitudinal tracking | Employees of corporate clients; affinity-group members; clinical patients | Launched Q3 CY2018 after 9 months of development; iterated through 2022 | Per-member annual SaaS subscription (ARR) |
| — | Aggregated, de-identified population dashboards for employers | Team-level brain-health and risk analytics; ROI reporting | HR / benefits leaders | 2018 onward | Bundled in corporate SaaS |
Clinical Insights / provider monitoring | Monitoring module for measurement-based care | Ongoing symptom and capacity tracking between visits | Providers, payers, insurers | 2019–2022 | SaaS licence; reimbursement-code strategy flagged (Mar 2020) |
HRV wearable functionality (Discrete and Continuous HRV) | Heart-rate-variability stress measurement using wrist wearables | Company said Discrete HRV was about 90% accurate versus chest-strap gold standard, and Continuous HRV about 4x more accurate than the next-best alternative with 30x signal resolution. Pilot: 6.4 engagements per day and a 25% stress reduction over 3 months | All channels | Launched March 2021 quarter | Upsell feature (pricing not disclosed) |
Mental Fitness 360 / GRIT integration (with IBM) | Total Brain embedded as core functionality in IBM's Thrive360 / Mental Fitness 360 platform and the GRIT app for transitioning veterans | Mental fitness, social connection and wellbeing tools for populations in transition | US Dept of Veterans Affairs; large government populations | Partnership Aug 2019; VA deployment 2021 (25,000 users; scalable to about 200,000) | Sub-licence through IBM; about A$570–590k ARR initial, up to about A$3.5m ARR at scale (company estimates) |
Everyday Health integration | Mental-health and fitness content embedded in Everyday Health web portal | Content delivery to 44m monthly unique users | Consumers via affinity partner | Signed Sept 2019 quarter | Licence/content fee |
D2C licence (Hamptons Life) | Exclusive perpetual global licence to build a consumer version | Separate D2C product | Consumers | — | A$6m upfront (recognized over 3 years), A$0.35m p.a. maintenance; TTB option on 50% equity |
focus@will B2C distribution | Revenue-share distribution through focus@will music-for-focus app | Monthly fee; revenue share | Consumers | Sept 2018 quarter | Subscription revenue share |
iSPOT-D research dataset | International Study to Predict Optimized Treatment for Depression; standardized biomarker and clinical data | Treatment-response prediction research | Pharma / biotech (Janssen R&D; Alto Neuroscience) | Study 2000s–2010s; licences late 2021 and Jan 2022 | One-off non-exclusive licence (Janssen US$2.2m) |
iSPOT-ADHD dataset | ADHD treatment-prediction study data | Precision psychiatry | Research, pharma | 2010s | — |
Brain Resource International Database (BRID) | Standardized brain database (EEG, cognition, emotion, genetics) built over about two decades; about A$50m cumulative R&D (RaaS) | Normative comparisons; underpins all products | Internal / licensing | 2000s onward | Not separately monetized except via licences |
WebNeuro (legacy) | Web-based neurocognitive and emotional assessment for clinicians | Depression evaluation; FDA clearance sought in 2012 | Clinicians | ~2009; superseded | Per-assessment (historical) |
MyBrainSolutions (legacy) | Brain-training and self-help platform; carried AARP users | Brain training; employer programs | Consumers; employers | ~2010; migrated to Total Brain 2018–19 (more than 600,000 users, 23 corporate clients and 5 channel partners transferred) | Subscription |
Brain Training Platform and Clinical Decision Support (legacy web products) | Earlier products built on iSPOT data | Training; clinician decision support | Consumers; clinicians | Pre-2018 | — |
“—” = not publicly disclosed.
Financial Narrative
Income statement
Notes and sources:
-
FY2018 revenue is derived as A$2,602,137 ÷ 0.995. The FY2018 loss is A$23,101,340 per the FY2019 Appendix 4E. Kalkine (Sept 2019) cited A$23,947,680. The discrepancy may reflect total versus attributable loss, and the 4E figure is preferred.
-
FY2019 revenue was A$2,602,137 and the loss A$8,570,754 (FY2019 Appendix 4E). No dividends were paid, recommended or declared in FY2019 (same source).
-
FY2020 revenue is derived from the +48.4% growth reported in the FY2020 Annual Report (cited by Motley Fool, Oct 2020). Expenses grew about 3% in FY2020 (same source).
-
FY2021 revenue of 3.694 comes from Preqin, currency unconfirmed. FY2021 growth is derived and should be treated as indicative only.
-
FY2022 revenue of A$8.42m and net loss of A$14.5m come from MarketScreener's aggregation of FY2022 results (released 30 Aug 2022). Eulerpool independently computes a -172.3% net margin for the latest year and -883.1% "a few years ago", which matches FY2022 and FY2018 above.
-
EBITDA forecasts by RaaS (July 2020) were not actuals and are excluded.
Revenue CAGR FY2018–FY2022: about 33.9% per year (A$2.62m to A$8.42m). This is flattered by FY2022 one-off data-licence income (Janssen US$2.2m, about A$3m at the time, plus Alto Neuroscience). On an ARR basis, the recurring business grew roughly 46% in CY2020 and then stalled through COVID-delayed sales cycles in 2021.
Trailing twelve months to 31 December 2022 (final reporting period)
Source: Simply Wall St (TTM based on H1 FY2023 report, released 28 Feb 2023). The negative gross profit probably reflects how staff and delivery costs were classified and transaction-related items in the period of the sale. It is not evidence of negative unit economics on its own.
Balance sheet and liquidity: notes and sources
Sources: RaaS Update (30 Jul 2020), net cash A$11.1m at 30 June 2020. Simply Wall St (Yahoo, 2019) noted no debt on the balance sheet. FY2018 debt of zero follows the A$14m debt-to-equity conversion during FY2018 (FY2018 Annual Report). FY2019 Appendix 4E gives NTA. MarketScreener gives FY2022 net debt of A$0.50m, consistent with the April 2022 A$1.28m convertible note from Zoltan Varga less remaining cash. A legacy aggregator (Eulerpool) shows "current assets" of A$14.69m and A$6.75m for unlabelled recent years; these could not be reconciled with filings and are excluded.
Cash flow
Sources: RaaS (30 Jul 2020): FY20 cash receipts A$4.997m, +81.5%; FY19 receipts derived as A$4.997m ÷ 1.815. Net outflows of A$6.647m (FY20) and A$7.021m (FY19) are from the RaaS cash table. The June 2020 quarter showed a net operating inflow of A$0.31m, helped by a A$1.0m upfront payment on a 3-year contract.
Quarterly cash indicator, September 2021 quarter: receipts A$0.554m; net operating outflow A$2.865m; staff costs about A$2.4m (Appendix 4C, via Stockhead). The annualized burn of about A$11.5m against roughly A$2m of quarterly receipts at best was the immediate cause of the strategic review.
Capex, free cash flow, dividends paid and buybacks: the company paid no dividends and conducted no buybacks while listed. The post-sale return of capital (A$0.0475 per share, 14 Feb 2023) was a liquidation-style distribution, not a buyback, even though the August 2022 plan contemplated a buy-back facility (RaaS, 8 Aug 2022).
Commentary on trends and inflections
Three phases stand out:
-
FY2017–FY2018 restructuring. Revenue fell 17% in FY2017. Under new CEO Louis Gagnon, FY2018 brought heavy losses (A$23.1m, inflated by restructuring and non-cash items around the A$14m debt conversion), a recapitalization, and the relaunch of the product as Total Brain.
-
FY2019–FY2020 rebuild. Revenue was flat at A$2.6m in FY2019 because growth in the corporate channel (+33%) was offset by the deliberate run-off of legacy lines (-36%). FY2020 delivered +48.4% revenue growth with costs up only about 3%, receipts up 81.5%, a strong balance sheet after the A$14m November 2019 placement, and A$11.1m of net cash.
-
FY2021–FY2022 stall and exit. COVID-19 caused delays of up to nine months in enterprise and government pipelines, and the IBM/VA contract slipped repeatedly through early 2021. ARR growth did not convert into revenue (FY2021 roughly flat). FY2022 revenue more than doubled only because of non-recurring data licences, while the loss widened to A$14.5m and the auditor flagged going-concern uncertainty. The company then sold itself.
The persistent gap between broker forecasts and actual results is striking. RaaS (July 2020) forecast A$5.4m revenue for FY2020, A$12.6m for FY2021 and A$21.5m for FY2022, with EBITDA reaching breakeven in FY2022. Actual FY2021 revenue was roughly A$3.7m, about 70% below forecast. This was the core reason for the de-rating.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity | Role | Notes |
|---|---|---|
Total Brain Limited (Australia) | ASX-listed parent; Sydney corporate office | Deregistered 12 May 2025 |
Brain Resource, Inc. (USA), trading as Total Brain | US operating subsidiary, San Francisco | Business assets sold to SonderMind (Preqin profile names this entity) |
Other subsidiaries | Not publicly disclosed in sources retrieved | — |
Segment Margins & Growth (%)
| Indicator | FY2018 | FY2019 | FY2020 |
|---|---|---|---|
Core corporate / employer revenue growth (%) | 28 | 33 | — |
Non-core / other revenue growth (%) | -33 | -36 | — |
Total revenue growth (%) | 8.5 | -0.5 | 48.4 |
Revenue by Segment
| Metric | Dec 2019 | Mar 2020 | Dec 2020 |
|---|---|---|---|
Minimum new ARR signed in quarter (AUD Mn) | — | 1.9 | — |
Total ARR (AUD Mn) | 2.74 | — | 4.0 |
Contracted ARR pipeline (AUD Mn) | — | — | 8.9 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome Statement and Margin Analysis (%)
| Metric | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|
Revenue (AUD Mn) | 2.62 | 2.60 | 3.86 | 3.69 | 8.42 |
Revenue growth (%) | 8.5 | -0.5 | 48.4 | -4.4 | 128.2 |
Net income attributable (AUD Mn) | -23.10 | -8.57 | — | — | -14.50 |
Net margin (%) | -883 | -329 | — | — | -172 |
Dividends per share (AUD cents) | — | 0 | — | — | — |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome Statement
| Metric (AUD Mn) | TTM Dec 2022 |
|---|---|
Revenue | 6.34 |
Cost of revenue | 10.01 |
Gross profit | -3.67 |
Other expenses | 11.05 |
Net earnings | -14.72 |
Key Financials and Per-Share Data
| Metric | FY2018 | FY2019 | FY2020 | FY2022 |
|---|---|---|---|---|
Cash and equivalents (AUD Mn) | — | — | 11.1 | — |
Total debt (AUD Mn) | 0 | 0 | 0 | — |
Net debt (AUD Mn) | — | — | -11.1 | 0.50 |
NTA per share (AUD cents, pre-consolidation) | 1.34 | 0.68 | — | — |
Key Financials
| Metric | FY2019 | FY2020 |
|---|---|---|
Cash receipts from customers (AUD Mn) | 2.75 | 5.00 |
Net operating outflow (AUD Mn) | 7.02 | 6.65 |
Average monthly net outflow (AUD Mn) | 0.585 | 0.554 |
Margin Analysis (%)
| Ratio | FY2019 | FY2022 |
|---|---|---|
Net margin (%) | -329 | -172 |
Debt / equity | 0 (no debt) | — |
Net debt / EBITDA | Not meaningful (negative EBITDA) | Not meaningful |
Share Price & Returns
| Reference point | Price (AUD) | Source |
|---|---|---|
5 Sep 2019 (pre-consolidation) | 0.052 | Kalkine (market cap about A$42m) |
Pre-pandemic, early 2020 (post-consolidation) | ~0.80 | Stockhead |
Late 2020 trading range | ~0.30 | Stockhead |
29 Jul 2020 | 0.32 | RaaS |
29 Oct 2020 | 0.38 | Motley Fool |
Jan 2021 high | ~0.45 | Stockhead |
Late 2021 (after Janssen licence) | 0.15 | Stockhead |
16 Jan 2023 | 0.046 | MarketScreener |
Capital return, 14 Feb 2023 | 0.0475 per share | deListed |
Share Price
| Metric | FY2019 | FY2020 |
|---|---|---|
Year-end reference share price (AUD) | 0.052 | 0.32 |
Dividends per share (AUD) | 0 | — |
Analyst Conclusions
Management guidance / consensus. None. The company has been deregistered and no securities exist. Any forward view now concerns the Total Brain assets inside SonderMind, which does not publish financials.
Retrospective bull-case arguments (as they were made in 2020–2021):
-
Irreplaceable science. The standardized database and iSPOT data could not be replicated cheaply. The Janssen (US$2.2m) and Alto licences proved third parties would pay for them.
-
Operating leverage. FY2020 showed revenue +48.4% on costs up about 3%, so incremental ARR should have dropped through toward breakeven.
-
Government scale optionality. IBM/VA expansion from 25,000 to about 200,000 users could have added about A$3.5m of ARR, nearly doubling the business.
Bear-case arguments (which proved correct):
-
Scale gap. ARR of about A$4m could not fund a competitive US go-to-market against peers backed by hundreds of millions of US dollars.
-
Conversion failure. Pipelines slipped (COVID delays of up to 9 months; IBM/VA delays). FY2021 revenue of about A$3.7m came in roughly 70% below sell-side forecasts.
-
Financing dependency. A quarterly burn of about A$2.9m against receipts of about A$0.55m (September 2021 quarter) made dilution or a sale unavoidable once equity markets tightened in 2022.
Catalysts / monitorables (next 12 months). For former shareholders: none, beyond confirming whether the liquidator made any further distribution after the A$0.0475 capital return (the 7 June 2024 loss declaration suggests no material further return). For the successor: whether SonderMind's measurement-based-care and AI tools visibly carry Total Brain's capacity assessments, whether SonderMind raises new capital or pursues an IPO, and whether the iSPOT datasets are licensed further.
Concluding analyst verdict.
Total Brain Limited is a closed file. Its story is common in Australian-listed life-science technology: world-class science, a sub-scale commercial engine, and a capital structure that could not bridge the gap. Over more than two decades, Brain Resource and then Total Brain built something genuinely distinctive: a standardized brain database and the iSPOT treatment-prediction studies. These were credible enough to attract IBM, the US Department of Veterans Affairs, AARP, Janssen and Alto Neuroscience. The 2018 relaunch as a mental-health SaaS platform was strategically sound, and FY2020 briefly showed the operating leverage the model promised: revenue up 48% on flat costs, positive quarterly operating cash flow, and A$11m of net cash.
The execution window closed quickly. COVID-19 hit exactly the long-cycle enterprise and government pipelines Total Brain depended on. Flagship deals slipped, and FY2021 revenue of roughly A$3.7m fell far short of forecasts above A$12m. The US employer mental-health market consolidated around full-stack providers that combined digital tools with therapy, a layer Total Brain never had. With quarterly burn near A$3m, a CEO and CFO departure in late 2021, and the auditor's going-concern emphasis in 2022, the board's US$10m sale to SonderMind was the rational outcome. The forfeited US$3m contingent payment underlined how little negotiating leverage remained. At about 1.7x trailing revenue, the exit valued the science well below its cumulative investment of about A$50m.
For investors, the lesson is that proprietary data creates option value but not a business model unless distribution is in place. Total Brain's real legacy now lives inside SonderMind's measurement-based-care platform, where the original thesis can still be tested: that objective brain-health measurement improves mental-health outcomes. It is no longer testable in public markets. Rating: Not applicable (entity deregistered). Historical assessment: scientifically strong, commercially sub-scale, ultimately a distressed strategic exit.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Role | Appointed | Background (as disclosed) |
|---|---|---|---|
Dr Evian Gordon (BSc Hons, MD, MBBCh, PhD) | Founder, Executive Chairman; Chief Medical Officer (by Jan 2022) | 8 Aug 2000 | Neuroscientist; founded Brain Resource; associated with more than 40 years of brain research per the SonderMind release (Nov 2022); moved across with the business to SonderMind |
Matthew (Matt) Mund | Interim CEO (from Nov 2021); previously COO | 3 Aug 2017 | Operations executive; COO from Nov 2020 per company records |
Simon Poidevin | President, Australia & New Zealand | 20 Mar 2020 | ANZ commercial lead |
Matthew Morgan | Non-Executive Director | 1 Mar 2016 | Authorized ASX releases in 2021; on-market buyer of TTB shares 2018–2019 |
David Torrible | Non-Executive Director | 1 Jun 2019 | Not detailed in sources |
Nestor Hinzack | Non-Executive Director (per deListed record) | Recorded 16 May 2001 | Long-tenured early director |
Nathan Jong; Phillip Hains | Company Secretaries | — | Company-secretarial services |
“—” = not publicly disclosed.
Board of Directors
| Name | Role | Tenure |
|---|---|---|
Louis Gagnon | Managing Director and CEO | 23 May 2017 – 12 Nov 2021 |
Emil Vasilev | CFO / VP Finance | ~2020 – 3 Dec 2021 |
David Daglio | Non-Executive Director | 13 Jan 2020 – 5 Dec 2022 |
Ajay Arora | Non-Executive Director | 8 May 2018 – 13 Jan 2020 |
Stephen Koslow | Non-Executive Director | 1 Mar 2016 – 1 Jun 2019 |
Gregory Bayer | CEO | 15 Mar 2012 – 23 May 2017 |
Dan Segal | Co-founder; COO/CFO; Executive Director | 8 Aug 2000 – 13 Oct 2016 |
Arthur Toga | Non-Executive Director | 16 May 2001 – 1 Mar 2016 |
Russell Jamison | Non-Executive Director | 5 Aug 2003 – 23 Jun 2014 |
Paul Keating | Non-Executive Director | 28 Aug 2001 – 6 Apr 2011 |
Major Shareholders
| Holder | Stake | Date | Source |
|---|---|---|---|
Mitsubishi UFJ Financial Group, Inc. | 5.17% (initial substantial holding) | 2019 | Kalkine |
Zoltan Varga | Convertible noteholder (A$1.28m) and shareholder; equity % not disclosed | Apr 2022 | RaaS, Aug 2022 |
Institutional placees (10 investors, Nov 2019 placement) | Not individually disclosed | Nov 2019 | ASX via deListed |
Competitive Landscape
Key Competitors
| Competitor | Segment overlap | Ownership | Relative positioning vs TTB |
|---|---|---|---|
Lyra Health | Employer mental-health benefits | Private (VC) | Far larger; full-stack therapy plus digital; dominant with Fortune 500 |
Spring Health | Employer mental health; precision matching | Private (VC) | Precision-psychiatry positioning that directly overlapped TTB's science narrative; much larger funding |
Modern Health | Employer mental wellbeing | Private (VC) | Global employer platform; tiered care |
Headspace (merged with Ginger, 2021) | Consumer and employer mindfulness; coaching | Private | Brand scale; employer distribution |
Calm | Consumer and employer wellbeing | Private | Consumer brand dominance |
Talkspace | Virtual therapy; employer and payer | Public (NASDAQ: TALK) | Therapy delivery rather than measurement |
Teladoc Health (BetterHelp, Livongo) | Virtual mental health at scale | Public (NYSE: TDOC) | Scale incumbent |
Lumos Labs (Lumosity) | Consumer brain training | Private | Overlapped TTB's legacy MyBrainSolutions brain-training proposition |
Happify / Twill | Digital mental-health and wellbeing programs | Private | Payer and employer programs |
Mindstrong | Digital biomarkers for mental health | Private (wound down; tech acquired by SonderMind) | Closest "measurement-based" analogue; a parallel failure |
Alto Neuroscience | Precision psychiatry (biomarker-guided drugs) | Public (NYSE: ANRO, IPO 2024) | Customer for TTB data rather than a competitor |
SonderMind | Therapy matching and delivery | Private | Became acquirer |
Competitor Detail
| Metric | Total Brain (FY2022) |
|---|---|
Revenue | A$8.42m |
Revenue growth | +128% (one-off licence driven) |
Net margin | -172% |
Recent Developments
Total Brain Limited produced almost no newsflow in this window because it was deregistered in May 2025. To give a useful register, Part A covers the entity and its successor in the true 18-month window. Part B covers the final 18 months of the listed company's material newsflow (August 2021 – March 2023).
Part A — Entity and successor (Apr 2025 – Oct 2026)
| Date | Event | Significance |
|---|---|---|
| 12 May 2025 | Total Brain Limited deregistered by ASIC | Entity ceases to exist; a CGT event for any remaining holders (deListed) |
| 2,025 | SonderMind expands in-network psychiatry to all 50 US states and DC (announced Nov 2025) | Shows the scale of the platform that now holds Total Brain's assets (Unify / AI Engineer org profile) |
| Aug 2025 | SonderMind provider network reaches about 13,000 clinicians | Distribution base for any Total Brain-derived measurement tools (AI Engineer org profile) |
| 4 Mar 2026 | SonderMind's President Jennifer Meyer is quoted in Octave's WiseMatch in-network-matching launch release | Shows SonderMind's focus on access and matching infrastructure (CB Insights / Business Wire) |
| 2,026 | SonderMind app promotes "Sonder", a 24/7 AI companion between sessions, and a SonderMind AI Suite governed by an AI Constitution | Measurement and self-care between sessions, the original Total Brain value proposition, now delivered through AI tooling (Similarweb listing; Business Wire) |
| 2,026 | SonderMind headcount reported at about 577 (Unify, Apr 2026) versus about 1.1k (GetLatka) | Sources conflict; both noted |
Part B — Final listed-company register (Aug 2021 – Mar 2023)
| # | Date | Event | Significance |
|---|---|---|---|
| 1 | Oct 2021 | September 2021 quarter 4C: receipts A$0.554m; operating outflow A$2.865m | Unsustainable burn |
| 2 | 12 Nov 2021 | CEO/MD Louis Gagnon departs; Matt Mund becomes Interim CEO | Leadership transition |
| 3 | 3 Dec 2021 | CFO Emil Vasilev departs | Finance leadership gap |
| 4 | Late 2021 | US$2.2m Janssen iSPOT-D licence; shares rise more than 50% to 15c | Non-dilutive cash |
| 5 | 5 Jan 2022 | Alto Neuroscience iSPOT-D licence | Second data monetization |
| 6 | 11 Mar 2022 | "Collaborative Care" thought-leadership publication | Repositions toward clinical integration |
| 7 | 4–5 Apr 2022 | Expects A$1.278m funding (convertible note, Zoltan Varga) | Bridge financing |
| 8 | 3 Aug 2022 | Trading halt pending significant transaction | Sale imminent |
| 9 | 4–5 Aug 2022 | Binding US$10m asset sale to SonderMind | Exit announced |
| 10 | 5 Aug 2022 | Plan disclosed to repay liabilities, return capital, delist and wind up | End-state defined |
| 11 | 22 Aug 2022 | Deadline passes for the clinical-services condition tied to the US$3m contingent payment | US$3m not payable |
| 12 | 30 Aug 2022 | FY2022 results: revenue A$8.42m, net loss A$14.5m | Final full-year results |
| 13 | Sep 2022 | Auditor raises going-concern doubt | Confirms funding pressure |
| 14 | 28–29 Sep 2022 | FY2022 Annual Report and AGM / transaction notice of meeting | Shareholder process |
| 15 | 30–31 Oct 2022 | Shareholder call; asset sale completed; shares up about 5% | Deal closed |
| 16 | 15 Nov 2022 | SonderMind announces the acquisition at HLTH 2022 | Public integration narrative |
| 17 | 5 Dec 2022 | Director David Daglio resigns | Board downsizing |
| 18 | 11 Jan 2023 | Capital-return payment mechanics (EFT) advised | Distribution process |
| 19 | 31 Jan 2023 | Shareholder call | Pre-EGM communication |
| 20 | 1 Feb 2023 | EGM approves delisting | Final approval |
| 21 | 14 Feb 2023 | A$0.0475 per share capital return paid; delisting date (1 Mar) announced | Cash to holders |
| 22 | 28 Feb 2023 | H1 FY2023 results; securities suspended at close | Final report |
| 23 | 1 Mar 2023 | Removed from ASX Official List | Listing ends |
| 24 | 9 Mar 2023 | Final shareholder call | Post-delisting communication |
| 25 | 7 Jun 2024 | Liquidator loss declaration | Tax event for holders |
| 26 | 2 Jul 2024 | Liquidator activity report | Winding-up progress |



